Mesenchymal Stem Cell Functionalization for Enhanced Therapeutic Applications
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
To date, the therapeutic efficacy of human mesenchymal stem cells (hMSCs) has been investigated in various clinical trials with moderate or, in some cases, inconsistent results. The still elusive reproducibility relates, in part, with constitutive differences in the cell preparation, translated into variable “cell potencies.” Other factors include poor cell homing and survival, and age-/disease-associated host tissue impairment. It is well accepted that within in vivo niches, MSCs exist as heterogeneous cell populations with different stemness propensities and supportive functions. Phenotype-based MSC purification of homogeneous subsets can result in cell populations with distinct biological functions. In addition, preclinical studies have shown that MSC functionalization in vitro, through cell priming, can boost their immunomodulatory, trophic, and reparative capacities in vivo. Therefore, in this review, we discuss how phenotype-based MSC purification and MSC priming technologies can contribute to an improved MSC-based product for safer and more effective therapeutic applications. Culture expansion of MSCs has detrimental effects on various cell characteristics and attributes (e.g., phenotypic changes and senescence), which, in addition to inherent interdonor variability, negatively impact the standardization and reproducibility of their therapeutic potential. The identification of innate distinct functional MSC subpopulations, as well as the description of ex vivo protocols aimed at maintaining phenotypes and enhancing specific functions have the potential to overcome these limitations. The incorporation of those approaches into cell-based therapy would significantly impact the field, as more reproducible clinical outcomes may be achieved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600
Rejuvenation of aged progenitor cells by exposure to a young systemic environment
Conboy, I. M., Conboy, M. J., Wagers, A. J., Girma, E. R., Weissman, I. L., & Rando, T. A. (2005) · Nature · doi:10.1038/nature03260 · Cited by 2,287
Sacchetti, B., Funari, A., Michienzi, S., Di Cesare, S., Piersanti, S., Saggio, I., Tagliafico, E., Ferrari, S., Robey, P. G., Riminucci, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.025 · Cited by 2,226
Lee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., & Prockop, D. J. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.003 · Cited by 1,898
Bourin, P., Bunnell, B. A., Casteilla, L., Dominici, M., Katz, A. J., March, K. L., Redl, H., Rubin, J. P., Yoshimura, K., & Gimble, J. M. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.02.006 · Cited by 1,890
Caplan, A. I., & Correa, D. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.06.008 · Cited by 1,682 · cited 2×
“78 Once at the injured tissue, it is well accepted that MSCs exert immunomodulatory (for both innate and adaptive immunity) and trophic activities, 79,80 recently suggested to be collectively called ‘‘medicinal’’ signaling activities.”
Self-citationMesenchymal Stem Cell Homing: The Devil Is in the Details
Karp, J. M., & Leng Teo, G. S. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.02.001 · Cited by 1,445
Waterman, R. S., Tomchuck, S. L., Henkle, S. L., & Betancourt, A. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010088 · Cited by 1,238
Tormin, A., Li, O., Brune, J. C., Walsh, S., Schütz, B., Ehinger, M., Ditzel, N., Kassem, M., & Scheding, S. (2011) · Blood · doi:10.1182/blood-2010-08-304287 · Cited by 460 · cited 5×
“…found in elderly adults, compared with children, 9 it is possible that CD146 Neg cells represent a subset of ‘‘aged’’ BM MSCs; however, this is not consistent with Tormin et al. ’s data 7 that showed no difference in the clo-nogenicity between CD271 + CD146 + and CD271 + CD146 Neg subpopulations.”
InfluentialTREM and TREM-like receptors in inflammation and disease
Ford, J. W., & McVicar, D. W. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.01.009 · Cited by 434
YlÖstalo, J. H., Bartosh, T. J., Coble, K., & Prockop, D. J. (2012) · STEM CELLS · doi:10.1002/stem.1191 · Cited by 427
Bianco, P., & Robey, P. G. (2015) · Development · doi:10.1242/dev.102210 · Cited by 402
Guijarro-Muñoz, I., Compte, M., Álvarez-Cienfuegos, A., Álvarez-Vallina, L., & Sanz, L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.521161 · Cited by 342
Estrada, J. C., Albo, C., Benguría, A., Dopazo, A., López-Romero, P., Carrera-Quintanar, L., Roche, E., Clemente, E. P., Enríquez, J. A., Bernad, A., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.172 · Cited by 297 · cited 1×
“153 Therefore, further studies should carefully consider the long-term effects of hypoxia-primed MSCs in models of disease.”
Is CD34 truly a negative marker for mesenchymal stromal cells?
Lin, C.-S., Ning, H., Lin, G., & Lue, T. F. (2012) · Cytotherapy · doi:10.3109/14653249.2012.729817 · Cited by 239 · cited 3×
“As a result of different studies, CD34 had become another possible, but controversial marker for MSC subset selection from fresh BM aspirates (reviewed in Lin et al. 28 ).”
Perivascular support of human hematopoietic stem/progenitor cells
Corselli, M., Chin, C. J., Parekh, C., Sahaghian, A., Wang, W., Ge, S., Evseenko, D., Wang, X., Montelatici, E., Lazzari, L., et al. (2013) · Blood · doi:10.1182/blood-2012-08-451864 · Cited by 189
Espagnolle, N., Guilloton, F., Deschaseaux, F., Gadelorge, M., Sensébé, L., & Bourin, P. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12168 · Cited by 154
Cited by
Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
Wu, X., Jiang, J., Gu, Z., Zhang, J., Chen, Y., & Liu, X. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01855-9 · Cited by 343
Bowles, A. C., Kouroupis, D., Willman, M. A., Perucca Orfei, C., Agarwal, A., & Correa, D. (2020) · Stem Cells · doi:10.1002/stem.3196 · Cited by 120
Self-citationHuman infrapatellar fat pad mesenchymal stem cells show immunomodulatory exosomal signatures
Kouroupis, D., Kaplan, L. D., & Best, T. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-07569-7 · Cited by 50
Self-citation
Metadata
- Authors
- Kouroupis, D., Sanjurjo-Rodriguez, C., Jones, E., & Correa, D.
- Venue
- Tissue Engineering Part B: Reviews
- Publisher
- SAGE Publications
- Published
- 2019-02
- Volume
- 25
- Issue
- 1
- Pages
- 55-77
- ISSN
- 1937-3368 (ISSN-L)
- 1937-3376
- OpenAlex
- W2889058371
- Cited by
- 92
- References
- 17
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.